Modern treatment of
glioblastoma multiforme (GBM) is based on neurosurgical methods combined with
radiotherapy and
chemotherapy. The prognosis for patients with GBM is extremely poor. Often, complete removal of the
tumor is impossible and it often recurs. Therefore, in addition to standard regimens, modern methods such as modulated electrohyperthermia,
monoclonal antibodies and individualised multimodal
immunotherapy (IMI) based on
vaccines and oncolytic viruses are also used in the treatment of GBM. Radioiodine
therapy (RIT) also holds out hope for an effective treatment of this extremely aggressive
brain tumor. The expression of the
sodium iodide symporter (NIS) gene has been proven to have a positive effect on the treatment of selected
cancers. Research confirm the presence of expression of this gene in GBM cells, although only in animal studies. Is it possible and therapeutically effective to treat GBM with RIT without the use of an exogenous NIS gene? The safety of
therapy is relevant, as the only more serious adverse effect may be
hypothyroidism. The use of RIT requires further clinical studies in patients. Perhaps it is worth revolutionizing GBM
therapy to give sufferers a "new life".